Literature DB >> 22664090

Adaptors in toll-like receptor signaling and their potential as therapeutic targets.

Thomas Ve1, Nicholas J Gay, Ashley Mansell, Bostjan Kobe, Stuart Kellie.   

Abstract

To initiate the innate immune response, Toll-like receptors (TLRs) associate with cytoplasmic adaptor proteins through TIR (Toll/interleukin-1 receptor) domain interactions. The four principal signaling adaptor proteins include MyD88, MAL, TRIF and TRAM, and the fifth protein SARM, involved in negative regulation of TLR pathways, is usually considered a part of the TIR domain-containing adaptor protein group. Other TIR domain-containing proteins have also been shown to regulate these signaling pathways, including ST2 and SIGIRR, as well as several bacterial and viral TIR domain-containing proteins that modulate these pathways as virulence factors. TLR pathways and the adaptor proteins are associated with a number of diseases, including infection, sepsis, inflammatory, allergic and autoimmune diseases and cancer. We review our current understanding of the structure and function of adaptor proteins and their regulatory proteins, their association with disease and their potential as therapeutic targets in human disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22664090     DOI: 10.2174/138945012803530260

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  27 in total

1.  Cloning, expression, purification, crystallization and preliminary X-ray crystallographic analysis of the TIR domain from the Brucella melitensis TIR-domain-containing protein TcpB.

Authors:  Mohammed Alaidarous; Thomas Ve; M Obayed Ullah; Eugene Valkov; Ashley Mansell; Mark A Schembri; Matthew J Sweet; Bostjan Kobe
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2013-09-28

Review 2.  Trial Watch: Toll-like receptor agonists in cancer immunotherapy.

Authors:  Melody Smith; Elena García-Martínez; Michael R Pitter; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-10-11       Impact factor: 8.110

3.  A non-uniform sampling approach enables studies of dilute and unstable proteins.

Authors:  Tomas Miljenović; Xinying Jia; Peter Lavrencic; Bostjan Kobe; Mehdi Mobli
Journal:  J Biomol NMR       Date:  2017-02-10       Impact factor: 2.835

4.  Structural basis of TIR-domain-assembly formation in MAL- and MyD88-dependent TLR4 signaling.

Authors:  Thomas Ve; Parimala R Vajjhala; Andrew Hedger; Tristan Croll; Frank DiMaio; Shane Horsefield; Xiong Yu; Peter Lavrencic; Zahid Hassan; Garry P Morgan; Ashley Mansell; Mehdi Mobli; Ailis O'Carroll; Brieuc Chauvin; Yann Gambin; Emma Sierecki; Michael J Landsberg; Katryn J Stacey; Edward H Egelman; Bostjan Kobe
Journal:  Nat Struct Mol Biol       Date:  2017-07-31       Impact factor: 15.369

Review 5.  TLR2 and TLR4 in autoimmune diseases: a comprehensive review.

Authors:  Yu Liu; Heng Yin; Ming Zhao; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

Review 6.  Cell Signaling Pathways That Regulate Antigen Presentation.

Authors:  Randy R Brutkiewicz
Journal:  J Immunol       Date:  2016-10-15       Impact factor: 5.422

7.  Relative Contributions of the cGAS-STING and TLR3 Signaling Pathways to Attenuation of Herpes Simplex Virus 1 Replication.

Authors:  Muhammad Bilal Latif; Rameez Raja; Patricia M Kessler; Ganes C Sen
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

8.  Crystallization and X-ray diffraction analysis of the N-terminal domain of the Toll-like receptor signalling adaptor protein TRIF/TICAM-1.

Authors:  M Obayed Ullah; Thomas Ve; Jameris Dkhar; Mohammed Alaidarous; Daniel J Ericsson; Matthew J Sweet; Ashley Mansell; Bostjan Kobe
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2013-06-28

Review 9.  Toll-like receptors and hypertension.

Authors:  Madhu V Singh; François M Abboud
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-06-11       Impact factor: 3.619

10.  MCPIP1 negatively regulates toll-like receptor 4 signaling and protects mice from LPS-induced septic shock.

Authors:  Shengping Huang; Ruidong Miao; Zhou Zhou; Tianyi Wang; Jianguo Liu; Gang Liu; Y Eugene Chen; Hong-Bo Xin; Jifeng Zhang; Mingui Fu
Journal:  Cell Signal       Date:  2013-02-17       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.